title: The effect of vanadyl treatment on vascular responsiveness of streptozotocin-diabetic rats.
abstract: Vanadyl sulphate has been demonstrated to possess insulin-like effects in streptozotocin (STZ) diabetic rats, including the normalization of hyperglycaemia and the prevention of diabetes-induced cardiac dysfunction. However, the effectiveness of vanadyl sulphate on diabetes-related vascular aberrations has not been questioned. Hence, in the present work, we have specifically addressed the question of whether chronic oral vanadyl sulphate treatment has any beneficial effect on diabetes-induced changes in vascular reactivity. Male albino rats were injected with a single intravenous dose of STZ (55 mg/kg). Vanadyl sulphate was administered in the drinking water at a concentration of 1 mg/ml from 7 days after the STZ injection and treatment was maintained for 10 weeks. Vanadyl intake was accompanied by decreased blood glucose and serum insulin levels. The effects of diabetes on vascular smooth muscle function were assessed by the responsiveness of aortae to noradrenaline and KCl. Contractile responses of the diabetic aortae were found to be significantly increased as compared with controls. However, there were no significant differences in pD2 values of the agonists in either of the groups. Treatment of diabetic rats with vanadyl sulphate completely prevented the increases in responsiveness of aortae to noradrenaline and KCl. The effect of diabetes on the fast and slow components of noradrenaline-induced contraction was also examined. Both components of the response to noradrenaline were significantly increased in diabetic aortae. These changes were also prevented by vanadyl sulphate treatment. The data demonstrate that 10-week vanadyl sulphate treatment results in improved vascular reactivity of diabetic rats.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, University of Ankara, Turkey.
authors.forename: A T
authors.initials: AT
authors.lastname: Ozçelikay
authors.forename: C
authors.initials: C
authors.lastname: Pekiner
authors.forename: N
authors.initials: N
authors.lastname: Ari
authors.forename: Y
authors.initials: Y
authors.lastname: Oztürk
authors.forename: A
authors.initials: A
authors.lastname: Ozüari
authors.forename: V M
authors.initials: VM
authors.lastname: Altan
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects* / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D013311:Streptozocin; D017968:Vanadium Compounds / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D017968:Vanadium Compounds; D013311:Streptozocin; D011189:Potassium Chloride; C034028:vanadyl sulfate; D009638:Norepinephrine